Leading Nation Pharma Proposes to Acquire All Equity of Conflux, Both Parties Have Entered into a Memorandum of Understanding

Hong Kong-listed Leading Nation Pharmaceutical & Biotechnology (00399) issued an announcement stating that on June 30, 2025, the company (as the buyer) has entered into a memorandum of understanding with the seller (Northwestern Foundation) and Conflux regarding the potential acquisition of all equity in the target company, conditional upon the target company completing the acquisition of Conflux assets in accordance with the agreement with the company.

Conflux is a limited company incorporated in Hong Kong, China, primarily engaged in the development of blockchain technology. The target company is a limited company to be incorporated in the Cayman Islands by the seller and wholly owned by the seller. The company is actively exploring new business opportunities to diversify its revenue sources and implement strategic plans to improve performance, and the company intends to expand its business to blockchain technology and enter the digital innovation industry.